Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C

In brief

The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection

Key facts

Study ID

NCT00512278

Run by

Nizar Zein

People needed

146

Starts

2007-07-01

Expected to finish

2012-05-01

Last updated by the study team

2017-09-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects, >18 years of age with proven chronic (greater than 6 months) hepatitis C infection (genotype 1) who have never been treated with pegylated interferon α-2b and /or ribavirin.
• Criteria for inclusion in this trial are as follows:
• Male or female, 18 years of age or older
• Positive HCV RNA, Genotype 1, treatment naïve (never received pegylated interferon and / or ribavirin)
• Evidence of chronic HCV infection for at least six months prior to screening
• Findings on liver biopsy within the past 36 months that are consistent with the presence of chronic hepatitis C infection.
• Negative hepatitis B surface antigen
• No evidence of hemochromatosis
• Hemoglobin ≥12 g/dL for females and ≥13 g/dL for males
• WBC ≥3.0 x 109/L and neutrophils ≥1.5 x 109/L
• Platelets ≥80 x109/L
• Direct Bilirubin WNL +/- 50% of central laboratory normal range. Total bilirubin ≤1.6.
• Albumin within normal limits
• Serum creatinine within normal limits.
• Serum thyroid stimulating hormone (TSH) levels within normal limits
• Men and women of childbearing potential must use two forms of adequate birth control measures for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.
• Subjects with a history of mild depression may be considered for entry into this study.
• No history of latent or active TB.

You may not qualify if…

• Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion and men with partners who are pregnant at baseline or intend to become pregnant within 6 months after the last infusion.
• Known allergy against infliximab, ribavirin, or pegylated interferon
• Decompensated liver disease characterized as decreased hepatic synthetic functioning with abnormal albumin and bilirubin levels, prolonged prothrombin time or complications including ascites or recent variceal bleeding
• have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidiomycosis (Valley Fever)
• History of autoimmune hepatitis or a history of poorly controlled autoimmune disease
• Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids
• Previous treatment with monoclonal antibodies or antibody fragments
• History of receiving human/murine recombinant products or a known allergy to murine products
• Documentation of seropositive for human immunodeficiency virus (HIV)
• History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results
• History of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the previous 3 months
• Opportunistic infection within 6 months prior to screening
• History of lymphoproliferative disease
• Currently have any known malignancy or have a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence
• Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease
• Treatment with any other therapeutic agent targeted at reducing TNF within 3 months of screening
• Presence of a transplanted solid organ
• Concomitant diagnosis or history of congestive heart failure

Where it is running

• Cedars-Sinai Medical Center, Center for Liver Disease and Transplantation — Los Angeles, California, United States
• Advanced Medical Research Center — Port Orange, Florida, United States
• University of Louisville — Louisville, Kentucky, United States
• Case Medical Center — Cleveland, Ohio, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• The Liver Institute at Methodist Dallas — Dallas, Texas, United States
• Brooke Army Medical Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.